Triggering Receptor Expressed On Myeloid Cells 1 (TREM1) Antibody

299€ (100 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Triggering Receptor Expressed On Myeloid Cells 1 (TREM1) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx104524
tested applications
WB, IHC, IF/ICC
Description
Polyclonal Antibody to Triggering Receptor Expressed On Myeloid Cells 1 (TREM1).
Documents del producto
Instrucciones
Data sheet
Product specifications
Category | Primary Antibodies |
Immunogen Target | Triggering Receptor Expressed On Myeloid Cells 1 (TREM1) |
Host | Rabbit |
Reactivity | Pig |
Recommended Dilution | WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
Clonality | Polyclonal |
Conjugation | Unconjugated |
Purification | Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography. |
Size 1 | 100 µl |
Size 2 | 200 µl |
Size 3 | 1 ml |
Form | Liquid |
Tested Applications | WB, IHC, IF/ICC |
Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
Availability | Shipped within 5-7 working days. |
Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
Dry Ice | No |
UniProt ID | Q6TYI6 |
Alias | Triggering receptor expressed on monocytes 1,CD354,TREM-1 |
Background | Antibody anti-TREM1 |
Status | RUO |
Descripción
Triggering receptor expressed on myeloid cells 1 (TREM1) is an immunoglobulin (Ig) superfamily receptor predominantly expressed on myeloid cells, such as neutrophils, monocytes, macrophages, and dendritic cells. TREM1 is recognized for its role in amplifying inflammatory responses during infections and other inflammatory conditions, and it plays a significant part in innate immune regulation. TREM1 is a potent activator of inflammatory responses and is known to amplify signaling from pattern recognition receptors (PRRs) such as toll-like receptors (TLRs). Through these amplifying actions, TREM1 enhances the immune system’s ability to clear pathogens but also has the potential to contribute to pathological inflammation. Triggering receptor expressed on myeloid cells 1 (TREM1) is an immunoglobulin (Ig) superfamily receptor predominantly expressed on myeloid cells, such as neutrophils, monocytes, macrophages, and dendritic cells. TREM1 is recognized for its role in amplifying inflammatory responses during infections and other inflammatory conditions, and it plays a significant part in innate immune regulation. TREM1 is a potent activator of inflammatory responses and is known to amplify signaling from pattern recognition receptors (PRRs) such as toll-like receptors (TLRs). Through these amplifying actions, TREM1 enhances the immune system’s ability to clear pathogens but also has the potential to contribute to pathological inflammation. TREM1 activation is linked with inflammatory cytokine production, chemotaxis, and cellular responses involved in pathogen clearance. In addition to pathogen responses, TREM1 is implicated in sterile inflammation, where it is upregulated during non-infectious inflammation, such as that observed in autoimmune diseases, cancer, and tissue damage. Its role in amplifying inflammatory cascades makes TREM1 a focal point for research into immune regulation and as a therapeutic target for controlling inflammation-related diseases.
Related Products

Mouse TREM-1(Triggering Receptor Expresses on Myeloid Cells-1) ELISA Kit
Ver Producto
Rat TREM-1(Triggering Receptor Expresses on Myeloid Cells-1) ELISA Kit
Ver Producto
anti- TREM1 antibody
Stimulates neutrophil and monocyte-mediated inflammatory responses. Triggers release of pro-inflammatory chemokines and cytokines, as well as increased surface expression of cell activation markers. Amplifier of inflammatory responses that are triggered by bacterial and fungal infections and is a crucial mediator of septic shock.
Ver Producto